|
gptkbp:instanceOf
|
anabolic steroid
|
|
gptkbp:alsoKnownAs
|
gptkb:Dianabol
gptkb:metandienone
|
|
gptkbp:ATCCode
|
A14AA03
|
|
gptkbp:bannedIn
|
gptkb:World_Anti-Doping_Agency
most countries for non-medical use
|
|
gptkbp:CASNumber
|
72-63-9
|
|
gptkbp:chemicalFormula
|
C20H28O2
|
|
gptkbp:controlledSubstanceSchedule
|
true
|
|
gptkbp:derivedFrom
|
testosterone
|
|
gptkbp:developedBy
|
gptkb:Ciba
|
|
gptkbp:eliminationHalfLife
|
3-6 hours
|
|
gptkbp:hasAnabolicRating
|
90-210
|
|
gptkbp:hasAndrogenicRating
|
40-60
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
methandrostenolone
|
|
gptkbp:introducedIn
|
1955
|
|
gptkbp:is17AlphaAlkylated
|
true
|
|
gptkbp:isEstrogenic
|
true
|
|
gptkbp:isHepatotoxic
|
true
|
|
gptkbp:isMisusedFor
|
doping
|
|
gptkbp:isNotApprovedFor
|
medical use in the UK
medical use in the US
|
|
gptkbp:isSynthetic
|
true
|
|
gptkbp:IUPACName
|
17β-hydroxy-17α-methylandrosta-1,4-dien-3-one
|
|
gptkbp:legalStatus
|
gptkb:Schedule_III_(US)
gptkb:Class_C_(UK)
|
|
gptkbp:marketedAs
|
gptkb:Anabol
gptkb:Danabol_DS
gptkb:Dianabol
gptkb:Metanabol
gptkb:Naposim
Averbol
|
|
gptkbp:meltingPoint
|
163-165°C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
300.44 g/mol
|
|
gptkbp:pregnancyCategory
|
gptkb:X_(US)
|
|
gptkbp:PubChem_CID
|
6321424
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular injection
|
|
gptkbp:sideEffect
|
acne
liver toxicity
gynecomastia
increased aggression
|
|
gptkbp:UNII
|
XB937A876B
|
|
gptkbp:usedBy
|
athletes
bodybuilders
|
|
gptkbp:usedFor
|
performance enhancement
muscle growth
|
|
gptkbp:bfsParent
|
gptkb:anabolic_steroids
|
|
gptkbp:bfsLayer
|
7
|